Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Alvotech and Finesse Announce Exciting Bio-Manufacturing Collaboration

Published: Saturday, March 22, 2014
Last Updated: Saturday, March 22, 2014
Bookmark and Share
Partnership will leverage Finesse’s SmartFactory single-use automation platform.

Alvotech and Finesse Solutions, Inc. have announced that they have entered into a partnership that will provide Alvotech with world-class, scalable, flexible and cost-efficient manufacturing and laboratory technology through the Finesse turnkey SmartFactory® GMP manufacturing platform suite.

SmartFactory® is a single-use cGMP bio-manufacturing capacity, which will allow Alvotech to rapidly expand its biosimilars business. Finesse’s customers will benefit from unprecedented access to Alvogen’s commercial, FDA approved, biomanufacturing facility.

Commenting, Dr. Andreas Herrmann, CEO of Alvotech, said: “This partnership allows us to leverage Finesse’s single-use bio-manufacturing automation platform, combining best-of-breed bio-process equipment from upstream through downstream. This strategic relationship provides us with much-needed additional manufacturing capacity and scale-up capabilities which will allow us to expedite our ambitions to become a global leader in the high-growth biopharmaceutical industry. The first manufacturing suite will be in place by the end of 2015.”

Dr. Barbara Paldus, CEO of Finesse, added: “Alvotech is capitalizing on the extraordinary flexibility afforded by SmartFactory, and together we will be able to implement cutting-edge, innovative solutions for established and development-stage biosimilars processes. The Alvotech facility will showcase our latest SMART technologies in process control, batch automation and data management. This partnership will also provide us with an important path to offer full-scale commercial manufacturing to our customers,”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
'Poison Pill' Fed to Deadly Virus
Researchers have created a genetic modification within a virus (with funny name), rendering it unable to replicate, mutate or cause illness.
World First Alzheimer's Vaccine Breakthrough
Researchers have made a breakthrough discovery towards an effective vaccine for Alzheimer's by targeting associated proteins.
Immunotherapy Drug Combo Targets Cancer
Mayo Clinic researchers identify potential immunotherapy drug combination that shows therapeutic effects against advanced and metastatic cancers.
Study Shows Sandoz Biosimilar Equivalent to Originator Drug
New data shows Sandoz biosimilar candidate has equivalent efficacy to originator etanercept following comparison in psoriasis.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Immunotherapy Reduces Rheumatoid-Linked Cardiovascular Risk
Study shows combination of two extra-low dose anticytokines reduces disease activity and cardiovascular events.
Viable HIV Vaccine Confirmed by Study
HIV Study in macaques confirms clinically viable vaccine opening the way for future treatment in humans.
Sanofi Working on Zika Vaccine with U.S. Army
Sanofi is working in conjunction with the U.S. Army to develop possible Zika vaccine at faster rate following research agreement.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!